Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Trastuzumab Emtansine Effective in Previously Treated HER2+ Advanced Breast Cancer
- Trastuzumab Emtansine Effective in Previously Treated HER2+ Advanced Breast Cancer
- Non–V600 BRAF Mutations Define a Distinct Subtype of Metastatic CRC
- Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer
- Breast Cancer Molecular Features and Survival Compared Between African and European Ancestry
- The Proportion of Patients With Breast Cancer Who Develop Bone Metastases
- Trastuzumab Plus Capecitabine With or Without Pertuzumab in HER2-Positive Metastatic Breast Cancer
- 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer
- Metronomic Chemotherapy for Metastatic Breast Cancer: A Meta-Analysis
- Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer